



Cyclopharm Limited

Half Year Presentation

August 2007

Highlights



- ☑ Strong balance sheet
- ☑ Strong trading cashflow
- ☑ First half profit impacted by expensing of investment in Molecular Imaging division and shift in sales product mix
- ☑ Development and implementation of Molecular Imaging division on target
- ☑ Strong underlying performance of the Technegas division
- ☑ Future growth of the business underpinned by capital investment by customers in TechnegasPlus generators

Profit & Loss



For the 6 months ended 30 June	2007 \$	2006 \$
Technegas Division		
Revenue	4,790,891	4,357,423
Profit before income tax	603,982	976,165
Molecular Imaging		
Revenue	-	-
Profit before income tax	(219,000)	-
Corporate		
Revenue	79,385	4,219
Profit before income tax	(354,836)	(21,475)
Consolidated		
Revenue	4,870,276	4,361,642
Profit before income tax (PBT)	30,146	954,690

Variance Analysis: PBT

Molecular Imaging establishment costs	\$0.22 m
Non-recurring patent and regulatory applications	\$0.14 m
Impact of change in sales mix - Generators vs PAS	\$0.45 m
Foreign exchange	\$0.06 m
Other	\$0.05 m
Total Variance	\$0.92 m

Comparison of 2007 and 2006 results is impacted by the formation of the Molecular Imaging division in late 2006 and the launch of the TechnegasPlus Generator in the 2nd half 2006.

Balance Sheet

cyclopharm

Nuclear Medicine




Balance Sheet Summary	30 June 2007	31 December 2006
Total Current Assets	\$6.16 m	\$7.01 m
Total Non-current Assets	\$3.17 m	\$2.20 m
Total Assets	\$9.33 m	\$9.21 m
Total Current Liabilities	\$2.91 m	\$4.42 m
Total Non-current Liabilities	\$0.37 m	\$5.35 m
Total Liabilities	\$3.28 m	\$9.77 m
Net Assets / (Liabilities)	\$6.05 m	(\$0.56 m)

Strong balance sheet

Gearing of 2% with the capacity to fund initial rollout of Molecular Imaging facilities and new Technegas markets

Significant improvement in working capital

Operating Cashflow



For the 6 months ended 30 June	2007	2006
Gross receipts from trading	\$5.75 m	\$4.40 m
Payments to trading partners	(\$5.26 m)	(\$3.55 m)
Other	(\$0.25 m)	(\$0.03 m)
Net cashflow from operating activities	\$0.24 m	\$0.82 m
Additional costs in the period:		
Molecular Imaging establishment costs	\$0.22 m	\$0.0 m
New product patent and regulatory application costs	\$0.14 m	\$0.0 m
Listed company costs	\$0.32 m	\$0.0 m
Normalised cashflow from trading activities	\$0.92 m	\$0.82 m

Strong trading cashflow

Molecular Imaging



Continued investment in development & establishment of 3 PET Central Pharmacies in Australia

Nearing completion of planning, design and site feasibility studies

Focus in 2nd half to shift to:

Securing locations, construction and fit-out of Pharmacies

Obtaining Good Manufacturing Practice (“GMP”) approval for premises and radiopharmaceuticals to be produced.

Technegas Divisional Review




Revenue from TechnegasPlus generators and PAS increased 15%

48 units installed in the first half of 2007 underpins future growth of the business through higher PAS sales

Regulatory approvals and new marketing authorisations in process for additional Technegas products

US FDA New Drug Application progressing



Technegas Divisional Review



Revenue Analysis for the 6 months ended 30 June		2007	2006	% Change
Sales:	TechnegasPlus	\$1.1 m	\$0.3 m	267%
	PAS	\$3.5 m	\$3.7 m	(5%)
Total Technegas sales revenue		\$4.6 m	\$4.0 m	15%

The launch of TechnegasPlus resulted in a shift of product mix:

For the 6 months ended 30 June		2007	2006	\$ Change
% of Total Revenue:	Generators	25%	9%	
	PAS	75%	91%	
Profit effect from reduced gross margin		71%	76%	(\$0.34 m)

Outlook



Investment in Molecular Imaging division to accelerate in second half

TechnegasPlus generator sales momentum expected to continue

Higher PAS sales in 2nd half to improve gross margin

Revision of EBIT guidance range for 2007 to \$2.4 m - \$2.7 m